High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma

Inclusion Criteria

• •Patients ≥ 18 years of age with aggressive B-cell non-Hodgkin lymphoma subtypes including, relapsed or refractory diffused large B-cell lymphoma (DLBCL), and transformed follicular lymphoma meeting at least one of the following criteria:
• •* Bone marrow involvement at the time of relapse or refractory disease and not appropriate for allogeneic transplantation.
• •* PET positive disease outside of one radiation port unless single-port disease treated with prior radiotherapy within the port, following \> or = to 2 cycles of salvage chemotherapy, still achieving chemosensitive status 1999 IWG criteria (section 12.2 and 12.383).
• •Creatinine ≤ 1.5 mg/100 ml (or measured 24 hour creatinine clearance of ≥ 50 cc/min)
• •Bilirubin \<2.0 mg/100 ml, AST and ALT \<3x the upper-limit of normal, PT and PTT \< 2x normal outside the setting of stable chronic anticoagulation therapy,
• •Adequate cardiac function (LVEF\>40%) as assessed by ECHO or MUGA scan performed within 1 month of treatment.
• •Adequate pulmonary function as assessed by DLCO of \> or = to 45% adjusted for hemoglobin.
• •Life expectancy of \> 3 months.
• •Patients previously treated with autologous or allogeneic bone marrow or stem cell transplantation are ineligible.
• •Other past or current malignancy unless in the opinion of the investigator it does not contraindicate participation in the study.
• •Uncontrolled bacterial, viral or fungal infection.
• •Patients with HIV, active hepatitis B or hepatitis C infection.